New biodegradable polymers to fight C. difficile infections
Novel polymer biomaterials combating C. difficile infection
This study is testing new biodegradable materials that could help treat Clostridium difficile infections, which cause diarrhea after taking antibiotics, by safely killing the harmful bacteria while leaving the good ones alone, and they can be taken by mouth for easier use.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Florida NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10685381 on NIH RePORTER |
What this research studies
This research focuses on developing innovative biodegradable polymer biomaterials that can effectively combat Clostridium difficile infections, which are a major cause of antibiotic-associated diarrhea. The approach involves creating polymers that mimic natural host-defense peptides, allowing them to disrupt bacterial membranes and kill C. difficile without harming beneficial gut bacteria. These polymers can be administered orally, making them a convenient treatment option. The research aims to demonstrate the efficacy of these polymers in eradicating infections in preclinical models, potentially offering a new solution for patients suffering from recurrent infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have experienced recurrent C. difficile infections and are seeking alternative treatment options.
Not a fit: Patients with infections caused by Gram-negative bacteria or those who do not have C. difficile infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and affordable treatment option for patients suffering from C. difficile infections.
How similar studies have performed: Previous research has shown promise in using similar biodegradable materials for antibacterial applications, indicating potential for success in this novel approach.
Where this research is happening
Tampa, United States
- University of South Florida — Tampa, United States (Active)
Researchers
- Principal investigator: Cai, Jianfeng — University of South Florida
- Study coordinator: Cai, Jianfeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.